Literature DB >> 32866347

The peroxisomal disorder spectrum and Heimler syndrome: Deep phenotyping and review of the literature.

Malena Daich Varela1, Priyam Jani2, Wadih M Zein1, Precilla D'Souza3, Lynne Wolfe4, Jennifer Chisholm5, Christopher Zalewski5, David Adams3,4, Blake M Warner2, Laryssa A Huryn1, Robert B Hufnagel1.   

Abstract

The spectrum of peroxisomal disorders is wide and comprises individuals that die in the first year of life, as well as people with sensorineural hearing loss, retinal dystrophy and amelogenesis imperfecta. In this article, we describe three patients; two diagnosed with Heimler syndrome and a third one with a mild-intermediate phenotype. We arrived at these diagnoses by conducting complete ophthalmic (National Eye Institute), auditory (National Institute of Deafness and Other Communication Disorders), and dental (National Institute of Dental and Craniofacial Research) evaluations, as well as laboratory and genetic testing. Retinal degeneration with macular cystic changes, amelogenesis imperfecta, and sensorineural hearing loss were features shared by the three patients. Patients A and C had pathogenic variants in PEX1 and Patient B, in PEX6. Besides analyzing these cases, we review the literature regarding mild peroxisomal disorders, their pathophysiology, genetics, differential diagnosis, diagnostic methods, and management. We suggest that peroxisomal disorders are considered in every child with sensorineural hearing loss and retinal degeneration. These patients should have a dental evaluation to rule out amelogenesis imperfecta as well as audiologic examination and laboratory testing including peroxisomal biomarkers and genetic testing. Appropriate diagnosis can lead to better genetic counseling and management of the associated comorbidities. Published [2020]. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  amelogenesis imperfect; heimler syndrome; peroxisomal disorders; retinal degeneration; sensorineural hearing loss

Mesh:

Substances:

Year:  2020        PMID: 32866347      PMCID: PMC8117942          DOI: 10.1002/ajmg.c.31823

Source DB:  PubMed          Journal:  Am J Med Genet C Semin Med Genet        ISSN: 1552-4868            Impact factor:   3.359


  71 in total

Review 1.  Biochemistry of mammalian peroxisomes revisited.

Authors:  Ronald J A Wanders; Hans R Waterham
Journal:  Annu Rev Biochem       Date:  2006       Impact factor: 23.643

2.  Diagnosing childhood-onset inborn errors of metabolism by next-generation sequencing.

Authors:  Arunabha Ghosh; Helene Schlecht; Lesley E Heptinstall; John K Bassett; Eleanor Cartwright; Sanjeev S Bhaskar; Jill Urquhart; Alexander Broomfield; Andrew Am Morris; Elisabeth Jameson; Bernd C Schwahn; John H Walter; Sofia Douzgou; Helen Murphy; Chris Hendriksz; Reena Sharma; Gisela Wilcox; Ellen Crushell; Ardeshir A Monavari; Richard Martin; Anne Doolan; Senthil Senniappan; Simon C Ramsden; Simon A Jones; Siddharth Banka
Journal:  Arch Dis Child       Date:  2017-05-03       Impact factor: 3.791

Review 3.  Skin manifestations in CDG.

Authors:  D Rymen; J Jaeken
Journal:  J Inherit Metab Dis       Date:  2014-02-20       Impact factor: 4.982

4.  Newly identified milder phenotype of peroxisome biogenesis disorder caused by mutated PEX3 gene.

Authors:  Shuji Matsui; Masuko Funahashi; Ayako Honda; Nobuyuki Shimozawa
Journal:  Brain Dev       Date:  2012-12-14       Impact factor: 1.961

5.  Investigational methods for peroxisomal disorders.

Authors:  Steven Steinberg; Richard Jones; Carol Tiffany; Ann Moser
Journal:  Curr Protoc Hum Genet       Date:  2008-07

6.  Abnormal profiles of polyunsaturated fatty acids in the brain, liver, kidney and retina of patients with peroxisomal disorders.

Authors:  M Martinez
Journal:  Brain Res       Date:  1992-06-26       Impact factor: 3.252

7.  Evaluation of C26:0-lysophosphatidylcholine and C26:0-carnitine as diagnostic markers for Zellweger spectrum disorders.

Authors:  Femke C C Klouwer; Sacha Ferdinandusse; Henk van Lenthe; Wim Kulik; Ronald J A Wanders; Bwee Tien Poll-The; Hans R Waterham; Frédéric M Vaz
Journal:  J Inherit Metab Dis       Date:  2017-07-04       Impact factor: 4.982

Review 8.  Therapy strategies for Usher syndrome Type 1C in the retina.

Authors:  Kerstin Nagel-Wolfrum; Timor Baasov; Uwe Wolfrum
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

9.  The PEX Gene Screen: molecular diagnosis of peroxisome biogenesis disorders in the Zellweger syndrome spectrum.

Authors:  Steven Steinberg; Li Chen; Liumei Wei; Ann Moser; Hugo Moser; Garry Cutting; Nancy Braverman
Journal:  Mol Genet Metab       Date:  2004-11       Impact factor: 4.797

10.  Heimler Syndrome Is Caused by Hypomorphic Mutations in the Peroxisome-Biogenesis Genes PEX1 and PEX6.

Authors:  Ilham Ratbi; Kim D Falkenberg; Manou Sommen; Nada Al-Sheqaih; Soukaina Guaoua; Geert Vandeweyer; Jill E Urquhart; Kate E Chandler; Simon G Williams; Neil A Roberts; Mustapha El Alloussi; Graeme C Black; Sacha Ferdinandusse; Hind Ramdi; Audrey Heimler; Alan Fryer; Sally-Ann Lynch; Nicola Cooper; Kai Ren Ong; Claire E L Smith; Christopher F Inglehearn; Alan J Mighell; Claire Elcock; James A Poulter; Marc Tischkowitz; Sally J Davies; Abdelaziz Sefiani; Aleksandr A Mironov; William G Newman; Hans R Waterham; Guy Van Camp
Journal:  Am J Hum Genet       Date:  2015-09-17       Impact factor: 11.025

View more
  3 in total

1.  Identification of a Homozygous PEX26 Mutation in a Heimler Syndrome Patient.

Authors:  Youn Jung Kim; Yuichi Abe; Young-Jae Kim; Yukio Fujiki; Jung-Wook Kim
Journal:  Genes (Basel)       Date:  2021-04-26       Impact factor: 4.096

2.  PEX6 Mutations in Peroxisomal Biogenesis Disorders: An Usher Syndrome Mimic.

Authors:  Matthew D Benson; Kimberly M Papp; Geoffrey A Casey; Alina Radziwon; Chris D St Laurent; Lance P Doucette; Ian M MacDonald
Journal:  Ophthalmol Sci       Date:  2021-05-25

3.  Introduction to the special issue on Ophthalmic Genetics: Vision in 2020.

Authors:  Robert B Hufnagel; Michael A Walter; Gavin Arno
Journal:  Am J Med Genet C Semin Med Genet       Date:  2020-08-31       Impact factor: 3.359

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.